Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News

FDA Approves FEIBA for Prophylactic Treatment to Treat Inhibitors

DEERFIELD, Ill., – Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) granted approval of Baxter’s FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors. […]

My Life, Our Future Launches Redesigned Website

It’s been an exciting year for My Life, Our Future, a nationwide initiative spearheaded by the National Hemophilia Foundation (NHF), offering a free genotyping test to people with hemophilia A and B. Now we’re pleased to announce the launch of the program’s newly redesigned website! As more and more hemophilia treatment centers (HTCs) across the […]

New Phase 3 Data Confirms Long-Lasting Characteristics of ALPROLIX™ and ELOCTATE™

CAMBRIDGE, Mass. & Stockholm –Today Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) announced new results from Phase 3 studies of their investigational long-lasting recombinant factor IX and VIII Fc fusion protein candidates for hemophilia B and A, ALPROLIXTM and ELOCTATETM, including an interim analysis of pediatric pharmacokinetics (PK) data. These interim […]

Data Shows Alprolix™ Effectively Controled Bleeding in Hemophilia B Patients

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIXTM, the companies’ investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B. The study appears in the Online First edition and will appear in the December […]

Leading Journal Publishes Pivotal Data For Biogen’s Eloctate™

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced that the detailed phase 3 data for the companies’ investigational long-lasting recombinant factor VIII Fc fusion protein candidate ELOCTATE™ were published online in Blood, the journal of the American Society of Hematology (ASH). Results from the A-LONG study showed that people […]

Novoeight® receives approval from the FDA

Bagsværd, Denmark  – Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics License Application (BLA) for recombinant coagulation factor VIII, Novoeight®. The FDA approved Novoeight® for use in adults and children with haemophilia A for:  Control and prevention of bleeding  Perioperative management  Routine prophylaxis to […]

Covidien Initiates a Voluntary Recall of Certain Lots of Monoject™ Prefill Flush Syringes

Mansfield, MA – Covidien today announced that it has initiated a voluntary recall of certain lots of Monoject™ prefill flush syringes. Reasons for Recall: This recall is being conducted due to the risk that a number of the syringes were filled with water but not subjected to the autoclave sterilization process. These products are labeled […]

Genetic Alliance has Launched a New Resource

The Genetic Alliance has launched a new resource at GenesInLife.org to help patients learn about genetics and health. In a time when searching for quality health information can be like searching for a needle in a haystack, Genetic Alliance is thrilled to announce the launch its newest public resource, Genesinlife.org. Genes in Life harmonizes many existing resources […]

First Ever Patient Needs Survey Launched for National Hemophilia Program

The National Hemophilia Program Coordinating Center (NHPCC), funded by the federal government through the American Thrombosis and Hemostasis Network, a nonprofit organization committed to advancing and improving care for individuals with bleeding and clotting disorders, announced rollout today of the first ever national hemophilia program patient needs survey. The NHPCC is working with over 130 […]

CSL Behring Joins American Thrombosis and Hemostasis Network

Riverwoods, IL – The American Thrombosis and Hemostasis Network (ATHN), a nonprofit organization committed to advancing and improving care for individuals with bleeding and clotting disorders, announced today that CSL Behring is providing funding to ATHN as a Supporting Member of the ATHN Industry Consortium. This funding will help ATHN continue to strengthen and enhance […]

Page 5 of 1512345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community